Nanoscope Therapeutics
11:45 AM - 12:00 PM (EDT), Wednesday, June 7, 2023 ・ Session Room 104C
Nanoscope Therapeutics is a late-stage clinical company developing an optogenetic platform to restore sight in patients suffering from inherited retinal disease and dry-AMD using ambient light-sensitive molecules and light-assisted gene therapy.
Nanoscope's lead asset, MCO-010, is currently in a pivotal trial in RP (retinitis pigmentosa) with data expected in Q1 2023. Additionally, a Ph2 trial evaluating MCO-010 in Stargardt macular degeneration is also being initiated. MCO-020, Nanoscope's follow-on asset for geographic atrophy in late-stage AMD patients, is currently in IND enabling studies.
Nanoscope utilizes ambient light-sensitive molecules to re-sensitize the retina toward low light levels. The Company's light-assisted gene therapy is highly targeted to geographic atrophies without perturbing the intact retina circuitry.
Nanoscope's lead asset, MCO-010, is currently in a pivotal trial in RP (retinitis pigmentosa) with data expected in Q1 2023. Additionally, a Ph2 trial evaluating MCO-010 in Stargardt macular degeneration is also being initiated. MCO-020, Nanoscope's follow-on asset for geographic atrophy in late-stage AMD patients, is currently in IND enabling studies.
Nanoscope utilizes ambient light-sensitive molecules to re-sensitize the retina toward low light levels. The Company's light-assisted gene therapy is highly targeted to geographic atrophies without perturbing the intact retina circuitry.
Ticker:
Not Provided
Exchange:
Not Provided
Company Type:
Not Provided
Company Website:
Company HQ State:
TX
Company HQ Country:
United States
Year Founded:
2017
Main Therapeutic Focus:
Gene/Cell Therapy
Lead Product in Development:
MCO-010 Optogenetic Gene Therapy for Inherited Retinal Dystrophies (IRDs)
Development Phase of Primary Product:
Phase II
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
